Krystal Stock Based Compensation vs Sale Purchase Of Stock Analysis

KRYS Stock

USD 159.29 1.20 0.75%

Krystal Biotech financial indicator trend analysis is infinitely more than just investigating Krystal Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Krystal Biotech is a good investment. Please check the relationship between Krystal Biotech Stock Based Compensation and its Sale Purchase Of Stock accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Stock Based Compensation vs Sale Purchase Of Stock

Stock Based Compensation vs Sale Purchase Of Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Krystal Biotech Stock Based Compensation account and Sale Purchase Of Stock. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Krystal Biotech's Stock Based Compensation and Sale Purchase Of Stock is 0.94. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Sale Purchase Of Stock in the same time period over historical financial statements of Krystal Biotech, assuming nothing else is changed. The correlation between historical values of Krystal Biotech's Stock Based Compensation and Sale Purchase Of Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Krystal Biotech are associated (or correlated) with its Sale Purchase Of Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Sale Purchase Of Stock has no effect on the direction of Stock Based Compensation i.e., Krystal Biotech's Stock Based Compensation and Sale Purchase Of Stock go up and down completely randomly.

Correlation Coefficient

0.94

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Sale Purchase Of Stock

Most indicators from Krystal Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Krystal Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.At this time, Krystal Biotech's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 2.1 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 164 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.8M	4.1M	5.0M	5.3M
Interest Income	197K	5.2M	22.6M	23.8M

Depreciation And Amortization Interest Income

Krystal Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Retained Earnings Total Equity	Net Invested Capital
Total Assets		0.81	0.93	0.99	1.0	0.77	0.99	0.96	-0.93	-0.95	0.7	0.86	0.98	0.92	0.9	-0.73	0.82	0.99	0.83	0.99	0.98	0.97	1.0	0.97	-0.95	0.93
Short Long Term Debt Total	0.81		0.61	0.85	0.81	0.76	0.85	0.76	-0.85	-0.77	0.69	0.86	0.73	0.86	0.88	-0.38	0.74	0.84	0.93	0.8	0.84	0.75	0.83	0.73	-0.86	0.81
Other Current Liab	0.93	0.61		0.93	0.93	0.61	0.9	0.97	-0.74	-0.96	0.6	0.66	0.98	0.8	0.78	-0.74	0.8	0.93	0.62	0.95	0.93	0.98	0.9	0.98	-0.88	0.86
Total Current Liabilities	0.99	0.85	0.93		0.98	0.73	0.98	0.98	-0.89	-0.97	0.72	0.83	0.98	0.91	0.91	-0.68	0.86	0.99	0.84	0.99	1.0	0.98	0.98	0.98	-0.97	0.93
Total Stockholder Equity	1.0	0.81	0.93	0.98		0.77	0.99	0.96	-0.93	-0.95	0.7	0.87	0.98	0.92	0.9	-0.73	0.82	0.99	0.82	0.99	0.98	0.96	1.0	0.97	-0.95	0.93
Other Liab	0.77	0.76	0.61	0.73	0.77		0.8	0.67	-0.85	-0.69	0.56	0.83	0.66	0.8	0.82	-0.45	0.48	0.78	0.7	0.74	0.7	0.66	0.81	0.66	-0.76	0.71
Net Tangible Assets	0.99	0.85	0.9	0.98	0.99	0.8		0.96	-0.94	-0.94	0.79	0.89	0.96	0.95	0.94	-0.63	0.86	1.0	0.87	0.98	0.98	0.95	0.99	0.95	-0.98	0.95
Property Plant And Equipment Net	0.96	0.76	0.97	0.98	0.96	0.67	0.96		-0.81	-0.99	0.68	0.75	0.99	0.87	0.87	-0.68	0.87	0.97	0.74	0.98	0.98	1.0	0.94	1.0	-0.95	0.91
Net Debt	-0.93	-0.85	-0.74	-0.89	-0.93	-0.85	-0.94	-0.81		0.8	-0.72	-0.97	-0.85	-0.92	-0.91	0.6	-0.73	-0.92	-0.91	-0.9	-0.88	-0.81	-0.95	-0.81	0.89	-0.89
Retained Earnings	-0.95	-0.77	-0.96	-0.97	-0.95	-0.69	-0.94	-0.99	0.8		-0.61	-0.74	-0.96	-0.88	-0.89	0.66	-0.86	-0.96	-0.73	-0.97	-0.97	-0.99	-0.93	-0.99	0.94	-0.91
Accounts Payable	0.7	0.69	0.6	0.72	0.7	0.56	0.79	0.68	-0.72	-0.61		0.74	0.7	0.77	0.72	-0.15	0.79	0.75	0.82	0.67	0.73	0.67	0.69	0.63	-0.83	0.75
Cash	0.86	0.86	0.66	0.83	0.87	0.83	0.89	0.75	-0.97	-0.74	0.74		0.78	0.96	0.93	-0.41	0.76	0.87	0.95	0.83	0.83	0.74	0.89	0.74	-0.87	0.91
Non Current Assets Total	0.98	0.73	0.98	0.98	0.98	0.66	0.96	0.99	-0.85	-0.96	0.7	0.78		0.88	0.85	-0.72	0.85	0.98	0.76	0.98	0.98	0.99	0.96	0.99	-0.94	0.92
Cash And Short Term Investments	0.92	0.86	0.8	0.91	0.92	0.8	0.95	0.87	-0.92	-0.88	0.77	0.96	0.88		0.98	-0.43	0.88	0.94	0.92	0.91	0.91	0.87	0.93	0.86	-0.95	0.98
Common Stock Shares Outstanding	0.9	0.88	0.78	0.91	0.9	0.82	0.94	0.87	-0.91	-0.89	0.72	0.93	0.85	0.98		-0.42	0.87	0.93	0.9	0.9	0.9	0.86	0.92	0.85	-0.95	0.95
Long Term Debt Total	-0.73	-0.38	-0.74	-0.68	-0.73	-0.45	-0.63	-0.68	0.6	0.66	-0.15	-0.41	-0.72	-0.43	-0.42		-0.32	-0.66	-0.33	-0.73	-0.67	-0.69	-0.72	-0.73	0.51	-0.48
Non Current Liabilities Total	0.82	0.74	0.8	0.86	0.82	0.48	0.86	0.87	-0.73	-0.86	0.79	0.76	0.85	0.88	0.87	-0.32		0.86	0.82	0.85	0.88	0.87	0.8	0.84	-0.91	0.92
Capital Surpluse	0.99	0.84	0.93	0.99	0.99	0.78	1.0	0.97	-0.92	-0.96	0.75	0.87	0.98	0.94	0.93	-0.66	0.86		0.85	0.99	0.99	0.97	0.99	0.97	-0.98	0.94
Other Current Assets	0.83	0.93	0.62	0.84	0.82	0.7	0.87	0.74	-0.91	-0.73	0.82	0.95	0.76	0.92	0.9	-0.33	0.82	0.85		0.8	0.84	0.74	0.84	0.72	-0.88	0.88
Other Stockholder Equity	0.99	0.8	0.95	0.99	0.99	0.74	0.98	0.98	-0.9	-0.97	0.67	0.83	0.98	0.91	0.9	-0.73	0.85	0.99	0.8		0.99	0.98	0.99	0.98	-0.95	0.93
Total Liab	0.98	0.84	0.93	1.0	0.98	0.7	0.98	0.98	-0.88	-0.97	0.73	0.83	0.98	0.91	0.9	-0.67	0.88	0.99	0.84	0.99		0.98	0.97	0.98	-0.97	0.94
Property Plant And Equipment Gross	0.97	0.75	0.98	0.98	0.96	0.66	0.95	1.0	-0.81	-0.99	0.67	0.74	0.99	0.87	0.86	-0.69	0.87	0.97	0.74	0.98	0.98		0.94	1.0	-0.94	0.91
Total Current Assets	1.0	0.83	0.9	0.98	1.0	0.81	0.99	0.94	-0.95	-0.93	0.69	0.89	0.96	0.93	0.92	-0.72	0.8	0.99	0.84	0.99	0.97	0.94		0.95	-0.95	0.93
Property Plant Equipment	0.97	0.73	0.98	0.98	0.97	0.66	0.95	1.0	-0.81	-0.99	0.63	0.74	0.99	0.86	0.85	-0.73	0.84	0.97	0.72	0.98	0.98	1.0	0.95		-0.93	0.9
Retained Earnings Total Equity	-0.95	-0.86	-0.88	-0.97	-0.95	-0.76	-0.98	-0.95	0.89	0.94	-0.83	-0.87	-0.94	-0.95	-0.95	0.51	-0.91	-0.98	-0.88	-0.95	-0.97	-0.94	-0.95	-0.93		-0.95
Net Invested Capital	0.93	0.81	0.86	0.93	0.93	0.71	0.95	0.91	-0.89	-0.91	0.75	0.91	0.92	0.98	0.95	-0.48	0.92	0.94	0.88	0.93	0.94	0.91	0.93	0.9	-0.95

Click cells to compare fundamentals

Krystal Biotech Account Relationship Matchups

Krystal Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	209.0M	310.8M	626.3M	558.5M	818.4M	859.3M
Other Current Liab	19K	(3.2M)	16.2M	21.7M	26.0M	27.3M
Total Current Liabilities	3.3M	15.5M	25.7M	28.8M	33.1M	34.7M
Total Stockholder Equity	202.9M	292.1M	593.6M	522.2M	778.6M	817.6M
Net Tangible Assets	202.9M	292.1M	593.6M	522.2M	600.6M	630.6M
Property Plant And Equipment Net	11.2M	34.2M	119.6M	169.7M	168.2M	176.6M
Net Debt	(184.3M)	(256.7M)	(333.2M)	(153.0M)	(350.2M)	(332.7M)
Retained Earnings	(39.0M)	(71.2M)	(140.8M)	(280.8M)	(269.8M)	(256.3M)
Accounts Payable	724K	2.1M	8.4M	4.0M	1.8M	2.5M
Cash	187.5M	268.3M	341.2M	161.9M	358.3M	202.5M
Non Current Assets Total	13.1M	35.8M	184.0M	174.7M	230.4M	242.0M
Non Currrent Assets Other	1.5M	1.6M	74K	324K	263K	249.9K
Cash And Short Term Investments	193.7M	271.3M	438.1M	379.2M	532.2M	271.9M
Common Stock Shares Outstanding	15.9M	18.8M	22.2M	25.5M	27.8M	18.0M
Liabilities And Stockholders Equity	209.0M	310.8M	626.3M	558.5M	818.4M	859.3M
Non Current Liabilities Total	2.8M	3.3M	7.0M	7.4M	6.6M	4.0M
Capital Surpluse	133.2M	242.0M	363.3M	734.5M	844.7M	886.9M
Other Current Assets	2.2M	7.6M	8.3M	4.6M	6.7M	4.2M
Other Stockholder Equity	242.0M	363.3M	734.5M	803.7M	1.0B	1.1B
Total Liab	6.1M	18.8M	32.7M	36.2M	39.7M	41.7M
Property Plant And Equipment Gross	11.2M	34.2M	123.8M	176.5M	181.1M	190.1M
Total Current Assets	195.9M	275.1M	442.3M	383.8M	587.9M	617.3M
Accumulated Other Comprehensive Income	10K	6K	(163K)	(728K)	638K	669.9K
Property Plant Equipment	11.2M	30.9M	119.6M	169.7M	195.2M	204.9M
Other Assets	1.5M	4.9M	74K	324K	372.6K	354.0K
Short Term Investments	6.2M	3.0M	96.9M	217.3M	173.9M	182.5M
Net Invested Capital	202.9M	292.1M	593.6M	522.2M	778.6M	401.1M
Net Working Capital	192.6M	259.6M	416.5M	354.9M	554.8M	304.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC